...
首页> 外文期刊>Advances in Experimental Medicine and Biology >Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients
【24h】

Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients

机译:非编码RNA实现大肠癌患者预后分层和治疗反应预测

获取原文
获取原文并翻译 | 示例

摘要

Colorectal cancer (CRC) is a heterogeneous disease and current treatment options for patients are associated with a wide range of outcomes and tumor responses. Although the traditional TNM staging system continues to serve as a crucial tool for estimating CRC prognosis and for stratification of treatment choices and long-term survival, it remains limited as it relies on macroscopic features and cases of surgical resection, fails to incorporate new molecular data and information, and cannot perfectly predict the variety of outcomes and responses to treatment associated with tumors of the same stage. Although additional histopathologic features have recently been applied in order to better classify individual tumors, the future might incorporate the use of novel molecular and genetic markers in order to maximize therapeutic outcome and to provide accurate prognosis. Such novel biomarkers, in addition to individual patient tumor phenotyp-ing and other validated genetic markers, could facilitate the prediction of risk of progression in CRC patients and help assess overall survival. Recent findings point to the emerging role of non-protein-coding regions of the genome in their contribution to the progression of cancer and tumor formation. Two major subclasses of non-coding RNAs (ncRNAs), microR-NAs and long non-coding RNAs, are often dysregulated in CRC and have demonstrated their diagnostic and prognostic potential as biomarkers. These ncRNAs are promising molecular classifiers and could assist in the stratification of patients into appropriate risk groups to guide therapeutic decisions and their expression patterns could help determine prognosis and predict therapeutic options in CRC.
机译:大肠癌(CRC)是一种异质性疾病,当前针对患者的治疗选择与广泛的结局和肿瘤反应相关。尽管传统的TNM分期系统继续作为评估CRC预后以及分层治疗选择和长期生存的关键工具,但由于其依赖于宏观特征和手术切除病例,因此仍然受到限制,未能纳入新的分子数据和信息,无法完全预测与同一阶段肿瘤相关的治疗结果和反应的多样性。尽管最近已应用其他组织病理学特征以更好地对单个肿瘤进行分类,但未来可能会结合使用新型分子和遗传标记,以最大程度地提高治疗效果并提供准确的预后。除个别患者的肿瘤表型和其他经过验证的遗传标记外,此类新型生物标记还可以促进对CRC患者进展风险的预测,并有助于评估总体生存率。最近的发现指出基因组的非蛋白质编码区在其对癌症和肿瘤形成的进展中的作用中出现了新的作用。非编码RNA(ncRNA)的两个主要亚类,microR-NA和长的非编码RNA,通常在CRC中失调,并已证明它们作为生物标志物的诊断和预后潜力。这些ncRNA是有前途的分子分类器,可帮助将患者分层为适当的风险组,以指导治疗决策,其表达方式可帮助确定CRC的预后并预测治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号